

## Anexo bibliográfico del artículo:

Buschiazio H, Dorati C, Iusef Venturini N, Cañas M, Urtasun MA, Marin GH, Prozzi GR, Rivadulla PA, Trionfetti M, Mordujovich Buschiazio P. Medicamentos retirados en otros países por problemas de seguridad. ¿Deben seguir presentes en el mercado farmacéutico argentino?. *Rev Fac Cien Med Univ Nac Cordoba*. 2022; 79(3): 241-247. doi: 10.31053/1853.0605.v79.n3.35443.

### Referencias bibliográficas 16-58:

16. Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. *Vademecum Nacional de Medicamentos* [Internet]. [citado 24 de septiembre de 2021]. Disponible en: <http://anmatvademecum.servicios.pami.org.ar>.
17. Grupo Alfa Beta. *Manual farmacéutico* [Internet]. Buenos Aires: Alfabet SACIFyS. 2016 [citado 24 de septiembre de 2021]. Disponible en: <https://www.alfabeta.net/precio>.
18. Commissioner O of the. U.S. Food and Drug Administration [Internet]. FDA. FDA; 2021 [citado 24 de septiembre de 2021]. Disponible en: <https://www.fda.gov/home>
19. Medicines & Health care products Regulatory Agency. *Products. Home* [Internet]. United Kingdom: MHRA; [citado 24 de septiembre de 2021]. Disponible en: <https://products.mhra.gov.uk>.
20. The Norwegian Medicines Agenc. *Legemiddelverket* [Internet]. Noruega. [citado 30 de septiembre de 2021]. Disponible en: <https://legemiddelverket.no/english>.
21. European Medicines Agency. *Science Medicines Health*. [Internet]. United Kingdom: European Medicines Agency; 1995. [citado 24 de septiembre de 2021]. Disponible en: <https://www.ema.europa.eu/en>.
22. Pergialiotis V, Amos P, Mavros MN, Pitsouni E, Athanasiou S, Falagas ME. Urinary tract analgesics for the treatment of patients with acute cystitis: where is the clinical evidence? *Expert Rev Anti Infect Ther*. 2012 Aug;10(8):875-9. doi: 10.1586/eri.12.72.
23. National Toxicology Program: 14th Report on Carcinogens [Internet]. USA. Department of Health and Human Services; 2016. [citado 24 de septiembre de 2021]. Disponible en: <https://ntp.niehs.nih.gov/qo/roc14>
24. Federal Register [Internet]. Determination That AZO GANTANOL (Phenazopyridine Hydrochloride, Sulfamethoxazole) Tablet, 100 Milligrams/500 Milligrams, and AZO GANTRISIN (Phenazopyridine Hydrochloride, Sulfisoxazole) Tablet, 50 Milligrams/500 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register. Office of the Federal Register, National Archives and Records Administration. 2014 Jun 12; 79(113):33757. Disponible en: <https://www.govinfo.gov/content/pkg/FR-2014-06-12/pdf/FR-2014-06-12.pdf>
25. Cañas M. Quién necesita a la Fenoltaleína? *Medicamentos y Salud*. 1998;2(3):142-43. Disponible en: [https://www.researchgate.net/publication/316554149\\_Quien\\_necesita\\_a\\_la\\_Fenoltaleina\\_Medicamentos\\_y\\_Salud\\_199823142-43](https://www.researchgate.net/publication/316554149_Quien_necesita_a_la_Fenoltaleina_Medicamentos_y_Salud_199823142-43)
26. World Health Organization. International Agency for Research on Cancer, editor. *Some antiviral and antineoplastic drugs, and other pharmaceutical agents*. Vol. 76. Lyon: IARC; 2000. Disponible en: <https://www.ncbi.nlm.nih.gov/books/NBK401398/>
27. Ali BH. Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. *Vet Res Commun*. 1999 Oct;23(6):343-60. doi: 10.1023/a:1006333608012.
28. World Health Organization. International Agency for Research on Cancer, editor. *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Some Food Additives, Feed Additives and Naturally Occurring Substances*. Vol. 31. Lyon: IARC; 1983. Disponible en: <https://publications.iarc.fr/publications/media/download/1579/6ee2bb2945de9540565266115886424ec5396608.pdf>
29. Kari FW, Huff JE, Leininger J, Haseman JK, Eustis SL. Toxicity and carcinogenicity of nitrofurazone in F344/N rats and B6C3F1 mice. *Food Chem Toxicol*. 1989 Feb;27(2):129-37. doi: 10.1016/0278-6915(89)90008-2.
30. National Toxicology Program. *NTP Toxicology and Carcinogenesis Studies of Nitrofurazone (CAS No. 59-87-0) in F344/N Rats and B6C3F1 Mice (Feed Studies)*. Natl Toxicol Program Tech Rep Ser. 1988;337:1-183.
31. World Health Organization. International. *Pharmaceuticals: Restrictions in Use and Availability Update of the 14th issue, 2010*. World Health Organization. [Internet]. Switzerland: WHO; 2010. Disponible en: <https://apps.who.int/iris/handle/10665/336531>
32. Brodie BB, Axelrod J The fate of acetanilide in man. *J Pharmacol Exp Ther*. 1948 Sep;94(1):29-38.
33. Thienes CH, Haley TJ. *Clinical toxicology*. 5th ed. Philadelphia: Lea &Febiger; 1972. 459 p.
34. Patty FA, George D, Clayton, Florence E, Clayton, Beard RR. *Patty's industrial hygiene and toxicology*. 3er ed. revised edition. Vol. 2 A: Toxicology, 1981. pp. XVIII 1467-2878.
35. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. *Br Heart J*. 1978 Oct;40(10):1069-118. doi: 10.1136/hrt.40.10.1069.
36. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. *Lancet*. 1984 Sep 15;2(8403):600-4.
37. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease—a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. *Am Heart J*. 2007 Nov;154(5):943-53. doi: 10.1016/j.ahj.2007.07.011.

38. Vassallo JD, Hicks SM, Daston GP, Lehman-McKeeman LD. Metabolic detoxification determines species differences in coumarin-induced hepatotoxicity. *Toxicol Sci.* 2004 Aug;80(2):249-57. doi: 10.1093/toxsci/kfh162.
39. Andréjak M, Gersberg M, Sgro C, Decocq G, Hamel JD, Morin M, Gras V. French pharmacovigilance survey evaluating the hepatic toxicity of coumarin. *Pharmacoepidemiol Drug Saf.* 1998 Aug;7 Suppl 1:S45-50. doi: 10.1002/(sici)1099-1557(199808)7:1+3.3.co;2-t.
40. Harrison WH. Ototoxicity of dihydrostreptomycin. *Q Bull Northwest Univ Med Sch.* 1954;28(3):271-3.
41. European Medicines Agency. Restrictions on the use of domperidone-containing medicines [Internet]. London; 2014. Disponible en: [https://www.ema.europa.eu/en/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines\\_en.pdf](https://www.ema.europa.eu/en/documents/referral/domperidone-article-31-referral-restrictions-use-domperidone-containing-medicines_en.pdf)
42. Rochoy M, Auffret M, Béné J, Gautier S. Antiémétiques et effets cardiaques potentiellement liés à un allongement de l'intervalle QT : analyse cas/non-cas dans la Base nationale de pharmacovigilance. *Revue D'épidémiologie et Santé Publique.* 2017;65(1):1-8. doi: 10.1016/j.respe.2016.06.335.
43. Inman WH, Rawson NS. Erythromycin estolate and jaundice. *Br Med J (Clin Res Ed).* 1983 Jun 18;286(6382):1954-5. doi: 10.1136/bmj.286.6382.1954.
44. Croteau D, Bergeron MG, LeBel M. Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography. *Antimicrob Agents Chemother.* 1988 Apr;32(4):561-5. doi: 10.1128/AAC.32.4.561.
45. Carlin W. Is there any justification for using phenazone in a local application prescribed for the treatment of acute otitis media? *BMJ.* 1987;294:1333. Citado en; Martindale W. *Martindale: The Complete Drug Reference.* 32nd ed. K. Parfitt, ed., Pharmaceutical Press, 1999.
46. Pranker TA. Hemolytic effects of drugs and chemical agents. *Clin Pharmacol Ther.* 1963 May-Jun;4:334-50. doi: 10.1002/cpt.196343334.
47. Delannoy A, Schmit JC. A granulocytosis after cutaneous contact with phenazone. *Eur J Haematol.* 1993 Feb;50(2):124. doi: 10.1111/j.1600-0609.1993.tb00153.x.
48. Hoyne AL, Larimore GW. Sulfathiazole as a cause of death: Report of patient with acute agranulocytosis. *JAMA.* 1941; 117(16):1353-1354. doi: 10.1001/jama.1941.72820420003013b.
49. Fisch C, Sacks HJ. High phthalylsulfathiazole (sulfathalidine) level associated with granulocytopenia; case report. *Gastroenterology.* 1950 Dec;16(4):782-4.
50. Riddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults. *Am J Gastroenterol.* 2016 May;111(5):602-22. doi: 10.1038/ajg.2016.126.
51. National Institute for Health and Care Excellence. Otitis media (acute): antimicrobial prescribing. NICE guideline [NG91]. United Kingdom: NISO; 2018;24. Disponible en: <https://www.nice.org.uk/guidance/ng91>.
52. Rosenfeld RM, Schwartz SR, Cannon CR, Roland PS, Simon GR, Kumar KA, Huang WW, Haskell HW, Robertson PJ; American Academy of Otolaryngology--Head and Neck Surgery Foundation. Clinical practice guideline: acute otitis externa executive summary. *Otolaryngol Head Neck Surg.* 2014 Feb;150(2):161-8. doi: 10.1177/0194599813517659.
53. Sakamoto C, Sugano K, Ota S, Sakaki N, Takahashi S, Yoshida Y, Tsukui T, Osawa H, Sakurai Y, Yoshino J, Mizokami Y, Mine T, Arakawa T, Kuwayama H, Saigenji K, Yakabi K, Chiba T, Shimosegawa T, Sheehan JE, Perez-Gutthann S, Yamaguchi T, Kaufman DW, Sato T, Kubota K, Terano A. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. *Eur J Clin Pharmacol.* 2006 Sep;62(9):765-72. doi: 10.1007/s00228-006-0171-6.
54. Lucchetta RC, Riveros BS, Pontarolo R, Radominski RB, Otuki MF, Fernandez-Llimos F, Correr CJ. Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. *Clinics (Sao Paulo).* 2017 May;72(5):317-324. doi: 10.6061/clinics/2017(05)10. Erratum in: *Clinics (Sao Paulo).* 2018 Mar 15;73:e1err.
55. Filgueira de Negreiros II, Cavalcanti de Oliveira D, Rogério de Oliverira Figueredo M, Magalhaes Ferra DL, Santana Souza L, Moreira J, Gavioli EC. Perfil dos efeitos adversos e contraindicações dos fármacos moduladores do apetite: umarevisão sistemática. *Nutrire Rev. Soc. Bras. Aliment. Nutr.* 2011;36 (2):137:60.
56. Ministerio de Salud de la Nación. *Guía de Práctica Clínica Nacional sobre Diagnóstico y Tratamiento de la Obesidad en Adultos.* Buenos Aires; 2014.
57. Chen J, Liu W, Liu CM, Li T, Liang RH, Luo SJ. Pectin modifications: a review. *Crit Rev Food Sci Nutr.* 2015;55(12):1684-98. doi: 10.1080/10408398.2012.718722.
58. Thakur BR, Singh RK, Handa AK. Chemistry and uses of pectin--a review. *Crit Rev Food Sci Nutr.* 1997 Feb;37(1):47-73. doi: 10.1080/10408399709527767.